Tag: Amaranth

Amaranth Presented MAGNITUDE (98 micron) Nine-Month Follow-up Clinical Results and Introduced DEFIANCE (85 micron) BRS Development Plan at TCT

Coronary/Structural Heart by 0 comments

MOUNTAIN VIEW, CA , Sept. 24, 2018 (GLOBE NEWSWIRE) — Amaranth Medical, a medical device company developing next-generation bioresorbable scaffolds, provided an update on the company’s sirolimus-eluting bioresorbable scaffold (BRS) products at the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting during the following sessions: Didactic Session: Drug-Eluting Stents, Bioresorbable Scaffolds, and Coronary Drug-Coated Balloons, Part 2, Session […]

Continue Reading →

Amaranth Presented Interim Nine-Month Follow-up MAGNITUDE (98 micron) and Two-Year Follow-up APTITUDE (115 micron) Data at EuroPCR Symposium

Coronary/Structural Heart by 0 comments

MOUNTAIN VIEW, CA , May 23, 2018 (GLOBE NEWSWIRE) — Amaranth Medical, a medical device company developing next-generation bioresorbable scaffolds for the interventional cardiology market, provided an update on the company’s sirolimus-eluting bioresorbable scaffold (BRS) products during a satellite symposium during EuroPCR 2018, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions. The symposium, […]

Continue Reading →